MSA-01 in Multiple System Atrophy

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study of MSA-01 in Patients With Multiple System Atrophy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07446894

Acronym

MSA-01_P3

Enrollment

140

Registered

2026-03-03

Start date

2026-02-09

Completion date

2028-03-31

Last updated

2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy (MSA)

Brief summary

The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety. The primary question is: • Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score? Participants will be randomly assigned to receive MSA-01 or placebo for 12 months. They will attend regular clinic visits for safety and efficacy assessments and record their medication use and any side effects in a diary.

Detailed description

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with no established disease-modifying treatment. Evidence suggests that coenzyme Q10 (CoQ10) deficiency may contribute to MSA pathophysiology. MSA-01 (ubiquinol), a highly bioavailable form of CoQ10, demonstrated acceptable safety and potential efficacy in a prior phase II trial. This is a multicenter, randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of MSA-01 in patients with MSA. Approximately 140 participants will be randomized 1:1 to receive oral MSA-01 or placebo for 52 weeks. The primary endpoint is the change from baseline to Week 52 in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part 2 score. Secondary endpoints include additional clinical scales and safety assessments. Efficacy will be analyzed using a mixed-effects model for repeated measures. The study aims to determine whether MSA-01 slows clinical progression compared with placebo while maintaining an acceptable safety profile.

Interventions

DRUGMSA-01

Ubiquinol

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 79 Years

Healthy volunteers

Inclusion criteria

At the time of informed consent 1. Patients diagnosed as 'clinically established' or 'clinically probable' MSA based on the revised MSA diagnostic criteria of the Movement Disorder Society (MDS). 2. Patients who are able to walk independently or with the use of assistive devices. 3. Patients who are able to attend outpatient visits at the participating study site. At the start of study drug administration 4. Patients who are able to discontinue the use of CoQ10 supplements.

Exclusion criteria

1. Patients with severe neurological disorders, other progressive movement disorders, or cognitive impairment. 2. Patients with severe liver disease. 3. Patients with a known history of hypersensitivity to any component of the investigational drug. 4. Pregnant women, breastfeeding women, or women who may be pregnant. 5. Patients who have previously participated in a clinical trial of MSA-01.

Design outcomes

Primary

Measure	Time frame
Change from baseline to Week 52 in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part 2 score	Baseline to Week 52

Secondary

Measure	Time frame
Change from baseline to Week 52 in the Barthel Index	Baseline to Week 52
Change from baseline to Week 52 in the Scale for the Assessment and Rating of Ataxia (SARA) score	Baseline to Week 52
Change from baseline to Week 52 in the Unified Multiple System Atrophy Rating Scale (UMSARS) Part 1 score	Baseline to Week 52

Countries

Japan

Contacts

CONTACTJun Mitsui

msa-office@umin.ac.jp+81-3-5800-9762

CONTACTIkue Wada